Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate

N/A

Report date: 2024/12/24 11:11:21

Base Information

Drug NameAnti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate
Drug Alias NameA mixture of anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion proteinT-GuardHENO-3SPV-T3aMabCD3-dgA/CD7-dgA
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionT-cell antigen CD7 inhibitorsAnti-CD3T lymphocytes inhibitors +[5] 
TargetsT cell surface glycoprotein CD3T-cell antigen CD7
Therapy Area/IndicationsGraft vs Host Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[9] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRadboud University Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHenogenXenikos Bv
Active IndicationsN/A
Inactive IndicationsGraft vs Host Disease

Other Information

ATC CodeN/A
Related LinksN/A